Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science



Rating:

Share or cite this content

Citations should be made in the following way:
I. Schouten (Leiden (ZH), Netherlands), A. Van Der Linden (Leiden (ZH), Netherlands), P. Hiemstra (Leiden (ZH), Netherlands), R. Mumford (Leiden (ZH), Netherlands), J. Stolk (Leiden (ZH), Netherlands). Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients. 554

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough Source: Eur Respir J 2016; 47: 35-38 Year: 2016 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Effect of corticosteroid therapy upon serum magnesium level in chronic asthmatic children Source: Annual Congress 2010 - Paediatric asthma, rhinitis and management Year: 2010 Effect of high dose alpha-1-antitrypsin infusion on neutrophil-generated fibrinogen fragments in type Z alpha-1-antitrypsin deficient patients Source: Eur Respir J 2004; 24: Suppl. 48, 307s Year: 2004 Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017 Year: 2017 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019 Year: 2019 The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Effect of discontinuation and readministration of inhaled human insulin on pulmonary safety in adult diabetes patients Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Influence of protein C activity on the PT/INR in patients receiving heparin Source: Eur Respir J 2003; 22: Suppl. 45, 221s Year: 2003 Effect of oral N-acetylcysteine treatment on systemic inflammatory status in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 716s Year: 2005 Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases Year: 2017 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Influence of a combination therapy versus steroid monotherapy on FeNO Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Pulmonary administration of alpha1-antitrypsin for the treatment of Alpha1-antitrypsin deficiency Source: Eur Respir J 2003; 22: Suppl. 45, 385s Year: 2003 Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy Source: Eur Respir Rev 2015; 24: 46-51 Year: 2015